Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
54.44%
Operating Margin
21.72%
Net Margin
23.42%
Efficiency Metrics
Revenue per Expense Ratio
1.26
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
63.37%
Income Tax Rate
0.00%
EPS
1.0100000000
Balance Sheet Analysis
Current Ratio
0.64
Cash Ratio
0.04
Working Capital
$-542.22M
Debt to Equity
0.64
Debt to Assets
35.31%
Equity Ratio
54.91%
Cash Flow Analysis
Operating Cash Flow Ratio
48.44%
Free Cash Flow Ratio
35.31%
CapEx to Revenue
13.12%
Dividends Paid
$333.44M
Stock Buybacks
$3.97M
Total Shareholder Returns
$337.41M
Cash Position Change
1.79%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 19.34%
Detailed Growth Metrics
Core Performance
Revenue
8.93%
Net Income
117.05%
EPS
102.00%
Operating Income
4.34%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
9.64%
Operating Cash Flow
10.99%
Free Cash Flow
14.77%
Balance Sheet Health
Assets
4.21%
Debt
-0.80%
Book Value per Share
2.91%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
19.34%
Shares Outstanding
3.65%
Long Term Trends
3Y Revenue/Share
16.25%
5Y Revenue/Share
22.75%
3Y Dividend/Share
143.04%
5Y Dividend/Share
115.41%